Single-Cell RNA Sequencing Reveals an Immune Landscape of CD4 + T Cells in Coronary Culprit Plaques With Acute Coronary Syndrome in Humans-Brief Report.

Background: Acute coronary syndrome (ACS) involves plaque-related thrombosis, causing primary ischemic cardiomyopathy or lethal arrhythmia. We previously demonstrated a unique immune landscape of myeloid cells in the culprit plaques causing ACS by using single-cell RNA sequencing. Here, we aimed to characterize T cells in a single-cell level, assess clonal expansion of T cells, and find a therapeutic target to prevent ACS.
Methods: We obtained the culprit lesion plaques from 4 patients with chronic coronary syndrome (chronic coronary syndrome plaques) and the culprit lesion plaques from 3 patients with ACS (ACS plaques) who were candidates for percutaneous coronary intervention with directional coronary atherectomy. Live CD45 ⁺ immune cells were sorted from each pooled plaque samples and applied to the 10× platform for single-cell RNA sequencing analysis. We also extracted RNA from other 3 ACS plaque samples and conducted unbiased TCR (T-cell receptor) repertoire analysis.
Results: CD4 ⁺ T cells were divided into 5 distinct clusters: effector, naive, cytotoxic, CCR7 ⁺ (C-C chemokine receptor type 7) central memory, and FOXP3 (forkhead box P3) ⁺ regulatory CD4 ⁺ T cells. The proportion of central memory CD4 ⁺ T cells was higher in the ACS plaques. Correspondingly, dendritic cells also tended to express more HLAs (human leukocyte antigens) and costimulatory molecules in the ACS plaques. The velocity analysis suggested the differentiation flow from central memory CD4 ⁺ T cells into effector CD4 ⁺ T cells and that from naive CD4 ⁺ T cells into central memory CD4 ⁺ T cells in the ACS plaques, which were not observed in the chronic coronary syndrome plaques. The bulk repertoire analysis revealed clonal expansion of TCRs in each patient with ACS and suggested that several peptides in the ACS plaques work as antigens and induced clonal expansion of CD4 ⁺ T cells.
Conclusions: For the first time, we revealed single cell-level characteristics of CD4 ⁺ T cells in patients with ACS. CD4 ⁺ T cells could be therapeutic targets of ACS.
Registration: URL: https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000046521; Unique identifier: UMIN000040747.
Competing Interests: Disclosures None.